Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.

about

Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.Dapagliflozin for the treatment of type 1 diabetes mellitus.Pharmacological Treatment in Diabetes Mellitus Type 1 - Insulin and What Else?

P2860

Q39000172-17ED8262-A7BF-4943-A35F-3467762C2CAA Q39354776-ED000B0B-97D2-4A5D-A9C7-BA06F9260BDD Q52562630-5CD53993-B31A-4C83-ACAB-5D8806082EC3

P2860

Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.

Item

http://www.wikidata.org/entity/Q38569449

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.

@en

type

Item

label

Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.

@en

prefLabel

Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.

@en

P1476

Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.

@en

P2093

Nasser Mikhail

http://www.w3.org/2001/XMLSchema#string

P2860

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.

Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes

Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.

Biology of human sodium glucose transporters.

The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.

P304

1381-1387

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2015.1061501

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26288025

http://www.w3.org/2001/XMLSchema#string

Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.

about

P2860

P2860

Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698